EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 3b-Like

Ensembl ID : ENSCVAG00000014452
Gene Symbol: LOC107093744
2 Cross references
227 Possible Orthologues:

Glutamate Receptor, Metabotropic 5b

Ensembl ID : ENSCVAG00000018004
Gene Symbol: GRM5B
1 Cross references
217 Possible Orthologues:

Glutaminase

Ensembl ID : ENSCVAG00000006160
Gene Symbol: GLS
3 Cross references
236 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSCVAG00000004760
Gene Symbol: LOC107103241
2 Cross references
225 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSCVAG00000015103
Gene Symbol: GSK3A
3 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSCVAG00000014037
Gene Symbol: GSK3B
3 Cross references
208 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSCVAG00000020363
Gene Symbol: LOC107090180
3 Cross references
181 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSCVAG00000021768
Gene Symbol: LOC107095257
2 Cross references
191 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSCVAG00000021235
Gene Symbol: LOC107095300
2 Cross references
1073 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSCVAG00000012335
Gene Symbol: LOC107095469
2 Cross references
1041 Possible Orthologues:

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSCVAG00000016245
Gene Symbol: LOC107083037
3 Cross references
233 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSCVAG00000019020
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).